Bristol Myers Squibb presents initial results for Zenbexus™ (Iberdomide) combined with Daratumumab from the Phase 3 EXCALIBER-RRMM trial in relapsed or refractory multiple myeloma.

Observed price moves

• BMY+0.27%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.